UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~October 2611, 2018

Oncolix, Inc.

(Exact name of registrant as specified in its charter)

Florida

333-192405

46-3046340

(state or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

14405 Walters Road, Suite 780

Houston, TX

77014

(address of principal executive offices)

(zip code)

281-402-3167

(registrant’s telephone number, including area code)

~~_____________________________________________~~___________________________________________ (former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Indicate~~Item ~~by check mark whether the registrant is an emerging growth company as defined in [sic] Rule 405 of the Securities Act of 1933 (§230~~7.~~405~~01 ofRegulation ~~this~~FD ~~chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).~~Disclosure

xOncolix, ~~Emerging~~Inc. ~~growth~~(“Oncolix” ~~company~~or the “Company”) is furnishing this information pursuant to Item 7.01 of this Current Report, which information shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information furnished pursuant to Item 7.01 in the Report that is required to be disclosed solely by Regulation FD.

IfOn anOctober ~~emerging~~1, ~~growth~~2018, ~~company~~Oncolix and IGL Pharma, ~~indicate~~Inc. by(“IGLP”) ~~check~~entered ~~mark~~into ifa ~~the~~patent ~~registrant~~and ~~has~~technology ~~elected~~license ~~not~~agreement and trademark assignment wherein IGLP hereby granted to ~~use~~Oncolix ~~the~~a ~~extended~~royalty-bearing, ~~transition~~sublicensable, ~~period~~exclusive license to a novel drug for ~~complying~~the ~~with~~potential ~~any~~treatment ~~new~~of orosteosarcoma, ~~revised~~bone ~~financial~~metastases ~~accounting~~and ~~standards~~bone ~~provided~~marrow ~~pursuant~~ablation. Included in this license are the rights to ~~Section~~manufacture, ~~13(~~have manufactured, use, import, offer to sell and/or sell products. The license includes a) ofcustomary upfront payment, milestone payments and royalties on product net sales in exchange for the ~~Exchange~~exclusive ~~Act.~~global orights to the drug.

~~Item~~Osteosarcoma 5is a fairly rare disease (U.02S. ~~Departure~~incidence of ~~Directors~~800 orto ~~Certain~~900 ~~Officers;~~patients) ~~Election~~that ofaffects ~~Directors;~~both ~~Appointment~~adolescents ofand ~~Certain~~adults. ~~Officers;~~While ~~Compensatory~~the ~~Arrangements~~cure ofrate ~~Certain~~in ~~Officers~~local osteosarcoma is about 70%, in metastatic disease it is fatal. In addition to the need for better therapies to treat the disease, there is also a need to reduce the pain associated with bone cancers. Bone pain is associated with all bone cancers, including bone metastases, which often originate from prostrate and breast cancer.

OnAlthough ~~June~~osteosarcoma ~~26,~~will ~~2018~~be our first target, the ~~Board~~preclinical ofdata ~~Directors~~demonstrate ofthat ~~Oncolix,~~this ~~Inc.~~drug ~~(the~~may ~~“Company”)~~be ~~voted~~effective tofor ~~increase~~ the ~~number~~treatment of ~~Directors~~bone tometastases ~~five~~and ~~from~~bone ~~the~~marrow ~~current~~ablation. ~~four,~~Bone ~~and~~marrow ~~elected~~ablation ~~Sherry~~is ~~Grisewood~~a toviable ~~serve~~option asfor amany ~~Director~~cancers, ~~until~~including ~~her~~leukemia, ~~resignation~~lymphoma orand ~~replacement~~sickle bycell ~~action~~anemia. ofIn the ~~stockholders~~case of ~~the~~sickle ~~Company.~~cell ~~After~~anemia, ~~her~~bone ~~election,~~marrow ablation is the ~~Board~~only ofknown ~~Directors~~cure. isThe ~~comprised~~current ofstandard ~~Ms.~~for ~~Grisewood,~~bone ~~Dr.~~marrow ~~John~~ablation ~~Holaday,~~is ~~Dale~~high ~~Zajicek~~doses of chemotherapy, ~~Dr.~~which ~~Jerry~~are ~~Youkey,~~known ~~and~~to ~~Michael~~cause ~~Redman,~~significant ~~the~~side ~~CEO~~effects.

~~Ms.~~Item Grisewood is an experienced financial professional with over 30 years’ experience in investment banking, advisory and research capacities across a wide variety of equity investment and corporate-directed activities, primarily for early stage life science, med-device and related technology companies9.01 ~~She~~Financial ~~has~~Statements ~~participated in over 80 transactions involving initial public offerings, secondaries, private placements, M&A~~ and ~~licensing/strategic collaborations~~Exhibits. Through her extensive corporate and academic interactions, she has experience with therapeutic areas such as immunotherapy, regenerative medicine, nucleic acid-based technologies and therapeutic medical devices that are being developed by US and non-US life science companies.

Ms. Grisewood has been active at the Board level for several early stage life science and medical device companies over the last 20 years. She is currently the Chairman of the Audit Committee and is a member of the Compensation Committee for Tapimmune, Inc., a NASDAQ-listed, clinical stage cancer immunotherapy company. She is a member of the Board of Directors of Mobitech Regenerative Medicine, Inc., an early stage orthopedics device company. She holds a Bachelor of Science degree, with Highest Honors, in Life Sciences from Ramapo College of New Jersey and earned the Chartered Financial Analyst (~~CFA~~b) ~~designation~~Exhibits. Sherry holds several FINRA licenses, including the general securities principal, investment banking and research principal licenses. She is a member of the CFA Institute, the Tissue Engineering and Regenerative Medicine Society International (TERMIS), the American Society of Gene and Cell Therapy, the European Federation of Biotechnology, Women in Bio and the Jazz Society of New Jersey.

~~The~~99.1 ~~Company~~Press ~~has~~release ~~concluded~~dated ~~that~~October ~~the specific experiences~~11, ~~qualifications and skills described above, including, without limitation, the significant background in finance, constitute the skill set necessary to serve as the Company’s Director.~~2018

~~The Company considers Ms. Grisewood, Dr. Holaday and Mr. Zajicek to be independent directors.~~2

As compensation, the Board has granted Ms. Grisewood an option to acquire 1,000,000 shares of Common Stock for $0.036 per share. The option expires June 26, 2023, and vests as follows: 1/3 in the date of grant, 1/3 on the first anniversary and 1/3 on the second anniversary. Ms. Grisewood will also receive cash compensation of $1,000 per month.SIGNATURES

~~The~~Pursuant ~~term~~to ofthe ~~each~~requirements ~~Director~~of ~~continues until~~ the ~~next~~Securities ~~election~~Exchange byAct ~~stockholders~~of 1934, orthe ~~their~~Registrant ~~resignation~~has orduly ~~removal~~caused bythis ~~action~~Report ofto ~~the~~be ~~majority~~signed ofon ~~stockholders.~~its ~~The~~behalf ~~next election~~ by ~~stockholders~~the isundersigned ~~expected~~hereunto induly ~~May 2019~~authorized.

	Oncolix, Inc.

Dated: October 11, 2018	By:	/s/ Michael T. Redman
		Michael T. Redman
		Chief Executive Officer

~~SIGNATURES~~3

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Oncolix, Inc.
Date: June 29, 2018	By:	/s/ Michael T. Redman
		Michael T. Redman
		President and Chief Executive Officer

Filing Compare · Oncolix, Inc.